Pyxis Oncology Past Earnings Performance
Past criteria checks 0/6
Pyxis Oncology's earnings have been declining at an average annual rate of -35%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-35.0%
Earnings growth rate
52.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -58.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18
Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13Revenue & Expenses BreakdownBeta
How Pyxis Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -74 | 31 | 50 |
| 30 Sep 23 | 0 | -94 | 33 | 68 |
| 30 Jun 23 | 0 | -99 | 33 | 72 |
| 31 Mar 23 | 0 | -109 | 35 | 78 |
| 31 Dec 22 | 0 | -121 | 37 | 86 |
| 30 Sep 22 | 0 | -101 | 38 | 64 |
| 30 Jun 22 | 0 | -88 | 33 | 52 |
| 31 Mar 22 | 0 | -71 | 27 | 38 |
| 31 Dec 21 | 0 | -76 | 19 | 51 |
| 30 Sep 21 | 0 | -64 | 11 | 47 |
| 30 Jun 21 | 0 | -53 | 8 | 42 |
| 31 Mar 21 | 0 | -47 | 6 | 40 |
| 31 Dec 20 | 0 | -13 | 4 | 9 |
Quality Earnings: PYXS is currently unprofitable.
Growing Profit Margin: PYXS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PYXS is unprofitable, and losses have increased over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare PYXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PYXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: PYXS has a negative Return on Equity (-58.7%), as it is currently unprofitable.